Citigroup Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.21 - $0.43 $166 - $340	-793 Reduced 21.22%	2,944 $0
Q3 2023 Nov 09, 2023	SELL	$0.28 - $0.93 $22 - $76	-82 Reduced 2.15%	3,737 $1,000
Q2 2023 Aug 10, 2023	BUY	$0.55 - $1.26 $210 - $482	383 Added 11.15%	3,819 $2,000
Q1 2023 May 11, 2023	SELL	$0.89 - $2.52 $7,348 - $20,807	-8,257 Reduced 70.61%	3,436 $3,000
Q4 2022 Feb 09, 2023	BUY	$1.02 - $7.48 $7,645 - $56,070	7,496 Added 178.6%	11,693 $13,000

Q3 2022 Nov 10, 2022	SELL	$6.04 - $9.66 $22,390 - $35,809	-3,707 Reduced 46.9%	4,197 $32,000
Q2 2022 Aug 10, 2022	BUY	$4.99 - $8.96 $9,061 - $16,271	1,816 Added 29.83%	7,904 $50,000
Q1 2022 May 12, 2022	SELL	$3.84 - $9.74 $32,140 - $81,523	-8,370 Reduced 57.89%	6,088 $50,000
Q4 2021 Feb 10, 2022	BUY	$5.12 - $8.19 $23,229 - $37,158	4,537 Added 45.73%	14,458 $75,000
Q3 2021 Nov 10, 2021	BUY	$6.68 - $9.1 $66,272 - $90,281	9,921 New	9,921 $66,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.